IDH2 and acute myeloid leukemia: This initial assessment is crucial for accurate risk assessment, initiation of induction therapy based on the presence of somatic mutations, e.g., FLT3-ITD, IDH mutations or KMT2A rearranged AML or CBF AML, and in making decisions regarding post-induction consolidation strategies.